GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SB-11285 overview

SB-11285 is under development for the treatment of immuno-oncology diseases including solid tumors including malignant melanoma, recurrent head and neck cancer squamous cell carcinoma, renal cell carcinoma, hepatocellular carcinoma, Merkle cell carcinoma, urothelial cancer, non-small cell lung cancer, gastric carcinoma, ovarian carcinoma, endometrial, triple negative breast cancer, cervical cancer, colorectal carcinoma. The drug candidate is administered through oral, intravenous and intratumor routes and it is developed based on proprietary small molecule nucleic acid hybrid (SMNH) platform technology. The drug candidate targets STING (Stimulator of Interferon Gene) protein.

It was under development for the treatment of pancreatic cancer, bladder cancer, and lymphoma.

F-star Therapeutics overview

F-star Therapeutics, formerly Spring Bank Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company. It discovers and develops novel class of therapeutics. The company develops nucleotide-based drugs and small molecule nucleic acid hybrids. Its development pipeline products include FS118, FS120, FS222, SB 11285, among other drug candidates. The company’s drug products are used in the rescuing CPI treatment failures, improving outcomes in CPI naive, PD-L1 low tumors, chemotherapy outcomes, CPI outcomes, addressing unmet needs. Its partners programs include multiple blood brain barrier, multiple immuno-oncology, STING inhibitor, multiple next generation bispecifics. Spring Bank is headquartered in Hopkinton, Massachusetts, the US.

For a complete picture of SB-11285’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

Smarter leaders trust GlobalData